High performance plasma amyloid-β biomarkers for Alzheimer’s disease

A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain

(2017) Jun Wang et al.   Nature Reviews Neurology

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment

(2016) Marina Boccardi et al.   JAMA Neurology

Clinical Impact of Amyloid Positron Emission Tomography—Is It Worth the Cost?

(2016) Richard J. Caselli et al.   JAMA Neurology

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

(2015) Sid E. O'Bryant et al.   Alzheimers & Dementia

Age and amyloid effects on human central nervous system amyloid-beta kinetics

(2015) Bruce W. Patterson et al.   ANNALS OF NEUROLOGY

Comparison of MR-less PiB SUVR quantification methods

(2015) Pierrick Bourgeat et al.   NEUROBIOLOGY OF AGING

Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers

(2014) S. M. Landau et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Mass++: A Visualization and Analysis Tool for Mass Spectrometry

(2014) Satoshi Tanaka et al.   JOURNAL OF PROTEOME RESEARCH

Amyloid and APOE  4 interact to influence short-term decline in preclinical Alzheimer disease

(2014) E. C. Mormino et al.   NEUROLOGY

The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials

(2014) Reisa Sperling et al.   NEURON

Novel plasma biomarker surrogating cerebral amyloid deposition

(2014) Naoki KANEKO et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

(2014) Naoki KANEKO et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Amyloid-beta 42 adsorption following serial tube transfer

(2014) Jamie Toombs et al.   Alzheimers Research & Therapy

CSF biomarker variability in the Alzheimer's Association quality control program

(2013) Niklas Mattsson et al.   Alzheimers & Dementia

The future of blood-based biomarkers for Alzheimer's disease

(2013) Kim Henriksen et al.   Alzheimers & Dementia

Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease

(2013) Alan Rembach et al.   Alzheimers & Dementia

Association of plasma and cortical amyloid beta is modulated by APOE ε4 status

(2013) Shanker Swaminathan et al.   Alzheimers & Dementia

Implementation and Validation of an Adaptive Template Registration Method for 18F-Flutemetamol Imaging Data

(2013) R. Lundqvist et al.   JOURNAL OF NUCLEAR MEDICINE

Comparison of Cerebrospinal Fluid Levels of Tau and Aβ 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms

(2012) David J. Irwin et al.   ARCHIVES OF NEUROLOGY

N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation

(2012) Dagmar Schlenzig et al.   JOURNAL OF NEUROCHEMISTRY

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology

(2011) Anne M. Fagan   ARCHIVES OF NEUROLOGY

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

(2011) Christopher M. Clark   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial

(2010) Rik Vandenberghe et al.   ANNALS OF NEUROLOGY

In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)

(2010) D. F. Wong et al.   JOURNAL OF NUCLEAR MEDICINE

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

(2010) Christopher C. Rowe et al.   NEUROBIOLOGY OF AGING

Overcoming synthetic Aβ peptide aging: a new approach to an age-old problem

(2009) Claudia Manzoni et al.   AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

(2009) Kathryn A Ellis et al.   INTERNATIONAL PSYCHOGERIATRICS

Relationships between biomarkers in aging and dementia

(2009) W. J. Jagust et al.   NEUROLOGY